ASCO-GU – J&J looks to a pasritamig combo
New data with pasritamig plus docetaxel support a recent pivotal start.
Vir tempts Astellas
The Japanese group pays $315m to co-develop an asset Vir got from a low-cost Sanofi deal.
Compass points the way towards its next readout
Progression-free and overall survival data from Companion-002 are due this quarter.
NK-cell engagers see another discontinuation
BeOne terminates a MUC1-targeting project.
The relentless march of VEGF bispecifics
Two new pivotal Chinese first-line trials have started in lung cancer.
Pfizer mimics pumitamig in gastroesophageal cancers
The company will start a phase 2/3 trial of PF-08634404 in March.
Regeneron bets big on Lynozyfic
The company is starting four new pivotal trials this year.
Roche follows Pfizer out of LTβR
The group also discontinues a mystery asset, and a Tecentriq trial in periadjuvant lung cancer.
